Source: Annual Congress 2003 - Treatment of asthma and COPD
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
C. McCowan, G. Hoskins, M. Stewart, R. G. Neville (Dundee, United Kingdom). Are patients who overuse short acting β2-agonists more likely to report high levels of asthma symptoms?. Eur Respir J 2003; 22: Suppl. 45, 2636

Member's Comments

No comment yet.

Related content which might interest you: "It‘s like living with a time bomb"– European patients‘ perspective on severe asthma symptoms Source: Annual Congress 2005 - Severe asthma: perception and management Year: 2005 Are patients who report persistent symptoms and days lost due to asthma more likely to be hospitalised in the subsequent year? Source: Eur Respir J 2002; 20: Suppl. 38, 204s Year: 2002 Which are the factors and causes that lead to omalizumab withdrawal in severe asthma patients? Source: International Congress 2018 – New developments in the treatment of asthma Year: 2018 Increasing proportion of children with asthma and atopic disease from high risk families. A consequence of parental recruitment? Source: Eur Respir J 2006; 28: Suppl. 50, 837s Year: 2006 Higher resource use and lower asthma-related QOL in patients with severe or difficult-to-treat asthma Source: Eur Respir J 2003; 22: Suppl. 45, 296s Year: 2003 Are there sub groups of children with asthma where FeNO guided treatment is associated with reduced risk for asthma attacks? Source: International Congress 2017 – Diagnostic tools in paediatric asthma Year: 2017 Are a degree of asthma therapy related to asthma control impairment? Source: Eur Respir J 2003; 22: Suppl. 45, 370s Year: 2003 Treatment of severe childhood asthma: what’s the evidence? Source: Annual Congress 2005 - Difficult asthma in children Year: 2005 Enough is enough: misuse of NIV in the treatment of chronic patients with exacerbation of symptoms? Source: Annual Congress 2013 –The dark side of the moon: when, why, and where I should not use NIV? Year: 2013 Do anxiety and depression affect patients‘ perceived level of asthma control? Source: Annual Congress 2008 - Markers and triggers of asthma Year: 2008 Comparison of COPD patients with high and low symptoms from a real-world US survey Source: International Congress 2015 – Non-inflammatory monitoring of airway diseases Year: 2015 Impact of physical activity level on symptomatology and functionality during an acute exacerbation in COPD patients. Source: International Congress 2018 – Exploring the importance of daily physical activity in chronic respiratory disease Year: 2018 How much is too much? The treatment of mild asthma Source: Eur Respir J 2007; 30: 403-406 Year: 2007 Physiological impairments and exacerbation risk in COPD patients with less symptom and no frequent exacerbation history. Source: Virtual Congress 2021 – Prediction of exacerbations in patients with COPD Year: 2021 Specific comorbidities and low adherence are independent risk factors for poorer asthma control and exacerbations in patients with difficult-to-control asthma Source: International Congress 2019 – Long-term evaluation and control of airway diseases Year: 2019 High use of SABAs is associated with higher exacerbation frequency Source: Virtual Congress 2020 – Asthma and cough: clinical trials and pharmacological insights Year: 2020 Dupilumab improves lung function and reduces severe exacerbations in uncontrolled persistent asthma patients with high and low reversibility Source: International Congress 2017 – Evolution or revolution in the treatment of asthma and allergies Year: 2017 FeNO threshold used to select severe asthma patients for Dupilumab may be inappropriate> Source: Virtual Congress 2021 – Severe asthma: evaluation using patient-reported outcome measures (PROMs) and biomarkers, comorbidities and treatments Year: 2021 Impact of morning symptoms experienced by COPD patients on exacerbation risk, rescue inhaler usage and normal daily activities Source: Annual Congress 2012 - COPD treatment and varia Year: 2012 Different causes of COPD exacerbation: unable or not to use bronchodilator drugs and journey to high altitude Source: Eur Respir J 2006; 28: Suppl. 50, 31s Year: 2006